Skip to main content
Top
Gepubliceerd in: Tijdschrift voor Kindergeneeskunde 5/2007

01-10-2007 | Artikelen

Diagnostiek en behandeling van de ziekte van Von Willebrand

Auteurs: Dr. K. Fijnvandraat, J. C. J. Eikenboom

Gepubliceerd in: Tijdschrift voor Kindergeneeskunde | Uitgave 5/2007

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Samenvatting

De ziekte van Von Willebrand is de meest voorkomende erfelijke bloederziekte en wordt gekenmerkt door een tekort aan werkzame Von Willebrand factor (vwf). Er zijn drie subtypen: bij type 1 en 3 is er sprake van een verlaagde plasmaconcentratie van vwf (kwantitatief defect), bij type 2 is er sprake van een verminderde functie van vwf (kwalitatief defect). Het subtype van de ziekte bepaalt in combinatie met de vwf-plasmaconcentratie welk bloedingspatroon een patiënt zal vertonen. De diagnose type 1 is vaak moeilijk met zekerheid te stellen door de grote spreiding en variabiliteit van de vwf-plasmaconcentraties in de normale populatie. Omdat bloedingssymptomen in de normale populatie ook vaak voorkomen, kan dit samenvallen met een bij toeval verlaagde vwf-concentratie, waardoor ten onrechte de diagnose ziekte van Von Willebrand type 1 wordt gesteld. Bij een lichte verlaging van de vwf-plasmaconcentratie die gepaard gaat met milde bloedingssymptomen is het beter om te concluderen dat er sprake is van een risicofactor voor bloedingen in plaats van een erfelijke ziekte. Hiermee wordt stigmatisering en eventuele overbehandeling voorkomen. Voor de behandeling van de ziekte van Von Willebrand kan gebruik worden gemaakt van ddavp, tranexaminezuur of vwf-concentraat. De keuze voor het geneesmiddel is afhankelijk van het type en de ernst van de bloeding of aard van de chirurgische ingreep.
Literatuur
go back to reference Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood. 1987;69:454-9.PubMed Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood. 1987;69:454-9.PubMed
go back to reference Sadler JE, Mannucci PM, Berntorp E, et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost. 2000;84:160-74.PubMed Sadler JE, Mannucci PM, Berntorp E, et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost. 2000;84:160-74.PubMed
go back to reference Laffan M, Brown SA, Collins PW, et al. The diagnosis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors’ Organization. Haemophilia. 2004;10:199-217.CrossRefPubMed Laffan M, Brown SA, Collins PW, et al. The diagnosis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors’ Organization. Haemophilia. 2004;10:199-217.CrossRefPubMed
go back to reference Posan E, McBane II RD, Grill DE, et al. Comparison of PFA-100 testing and bleeding time for detecting platelet hypofunction and von Willebrand disease in clinical practice. Thromb Haemost. 2003;90:483-90.PubMed Posan E, McBane II RD, Grill DE, et al. Comparison of PFA-100 testing and bleeding time for detecting platelet hypofunction and von Willebrand disease in clinical practice. Thromb Haemost. 2003;90:483-90.PubMed
go back to reference Harrison P. The role of PFA-100 testing in the investigation and management of haemostatic defects in children and adults. Br J Haematol. 2005;130:3-10.CrossRefPubMed Harrison P. The role of PFA-100 testing in the investigation and management of haemostatic defects in children and adults. Br J Haematol. 2005;130:3-10.CrossRefPubMed
go back to reference Dean JA, Blanchette VS, Carcao MD, et al. Von Willebrand disease in a pediatric-based population – comparison of type 1 diagnostic criteria and use of the PFA-100 and a von Willebrand factor/collagen-binding assay. Thromb Haemost. 2000; 84:401-9.PubMed Dean JA, Blanchette VS, Carcao MD, et al. Von Willebrand disease in a pediatric-based population – comparison of type 1 diagnostic criteria and use of the PFA-100 and a von Willebrand factor/collagen-binding assay. Thromb Haemost. 2000; 84:401-9.PubMed
go back to reference Cariappa R, Wilhite TR, Parvin CA, et al. Comparison of PFA-100 and bleeding time testing in pediatric patients with suspected hemorrhagic problems. J Pediatr Hematol Oncol. 2003;25:474-9.CrossRefPubMed Cariappa R, Wilhite TR, Parvin CA, et al. Comparison of PFA-100 and bleeding time testing in pediatric patients with suspected hemorrhagic problems. J Pediatr Hematol Oncol. 2003;25:474-9.CrossRefPubMed
go back to reference Sadler JE, Budde U, Eikenboom JCJ, et al. Update on the pathofysiology and classification of von Willebrand disease: a report of the subcommittee on von Willebrand factor. J Thromb Haemost. 2006;4:2103-14.CrossRefPubMed Sadler JE, Budde U, Eikenboom JCJ, et al. Update on the pathofysiology and classification of von Willebrand disease: a report of the subcommittee on von Willebrand factor. J Thromb Haemost. 2006;4:2103-14.CrossRefPubMed
go back to reference Sadler JE, Rodeghiero F. Provisional criteria for the diagnosis of von Willebrand disease type 1. J Thromb Haemost. 2005;3: 775-7.CrossRefPubMed Sadler JE, Rodeghiero F. Provisional criteria for the diagnosis of von Willebrand disease type 1. J Thromb Haemost. 2005;3: 775-7.CrossRefPubMed
go back to reference Silwer J von. Willebrand's disease in Sweden. Acta Paediatr Scand Suppl. 1973;238:1-159.PubMed Silwer J von. Willebrand's disease in Sweden. Acta Paediatr Scand Suppl. 1973;238:1-159.PubMed
go back to reference Lak M, Peyvandi F, Mannucci PM. Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease. Br J Haematol. 2000;111:1236-9.CrossRefPubMed Lak M, Peyvandi F, Mannucci PM. Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease. Br J Haematol. 2000;111:1236-9.CrossRefPubMed
go back to reference Tosetto A, Rodeghiero F, Castaman G, et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost. 2006;4:766-73.CrossRefPubMed Tosetto A, Rodeghiero F, Castaman G, et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost. 2006;4:766-73.CrossRefPubMed
go back to reference Kadir RA, Economides DL, Sabin CA, et al. Variations in coagulation factors in women: effects of age, ethnicity, menstrual cycle and Regular oral contraceptive. Thromb Haemost. 1999;82:1456-61.PubMed Kadir RA, Economides DL, Sabin CA, et al. Variations in coagulation factors in women: effects of age, ethnicity, menstrual cycle and Regular oral contraceptive. Thromb Haemost. 1999;82:1456-61.PubMed
go back to reference Onundarson PT, Gudmundsdottir BR, Arnfinnsdottir AV, et al. Von Willebrand factor does not vary during normal menstrual cycle. Thromb Haemost, 2001;85:183-4.PubMed Onundarson PT, Gudmundsdottir BR, Arnfinnsdottir AV, et al. Von Willebrand factor does not vary during normal menstrual cycle. Thromb Haemost, 2001;85:183-4.PubMed
go back to reference Miller Ch, Dilley AB, Drews C, et al. Changes in von Willebrand factor and factor VIII levels during the menstrual cycle. Thromb Haemost. 2002;87:1082-3. Miller Ch, Dilley AB, Drews C, et al. Changes in von Willebrand factor and factor VIII levels during the menstrual cycle. Thromb Haemost. 2002;87:1082-3.
go back to reference Eikenboom J, Marion V van, Putter H, et al. Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD). J Thromb Haemost. 2006;4:774-82.CrossRefPubMed Eikenboom J, Marion V van, Putter H, et al. Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD). J Thromb Haemost. 2006;4:774-82.CrossRefPubMed
go back to reference Goodeve A, Eikenboom J, Castaman G, et al. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD). Blood. 2007;109:112-21.CrossRefPubMed Goodeve A, Eikenboom J, Castaman G, et al. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD). Blood. 2007;109:112-21.CrossRefPubMed
go back to reference James PD, Notley C, Hegadorn C, et al. The mutational spectrum of type 1 von Willebrand disease: Results from a Canadian cohort study. Blood. 2007;109:145-54.CrossRefPubMed James PD, Notley C, Hegadorn C, et al. The mutational spectrum of type 1 von Willebrand disease: Results from a Canadian cohort study. Blood. 2007;109:145-54.CrossRefPubMed
go back to reference Sadler JE. Von Willebrand disease type 1: a diagnosis in search of a disease. Blood. 2003;101:2089-93.CrossRefPubMed Sadler JE. Von Willebrand disease type 1: a diagnosis in search of a disease. Blood. 2003;101:2089-93.CrossRefPubMed
go back to reference Mazurier C, Gaucher C, Jorieux S, et al. Biological effect of desmopressin in eight patients with type 2N (`Normandy’) von Willebrand disease. Br J Haematol. 1994;88:849-54.CrossRefPubMed Mazurier C, Gaucher C, Jorieux S, et al. Biological effect of desmopressin in eight patients with type 2N (`Normandy’) von Willebrand disease. Br J Haematol. 1994;88:849-54.CrossRefPubMed
go back to reference Holmberg L, Nilsson IM, Borge L, et al. Platelet aggregation induced by 1-desamino-8-D-arginine vasopressin (DDAVP) in type IIB von Willebrand's disease. N Engl J Med. 1983;309: 816-21.PubMedCrossRef Holmberg L, Nilsson IM, Borge L, et al. Platelet aggregation induced by 1-desamino-8-D-arginine vasopressin (DDAVP) in type IIB von Willebrand's disease. N Engl J Med. 1983;309: 816-21.PubMedCrossRef
go back to reference Lopez-Fernandez MF, Lopez-Berges C, Martin-Bernal JA, et al. Type IIB von Willebrand's disease associated with a complex thrombocytopenic thrombocytopathy. Am J Hematol. 1988;27:291-8.CrossRefPubMed Lopez-Fernandez MF, Lopez-Berges C, Martin-Bernal JA, et al. Type IIB von Willebrand's disease associated with a complex thrombocytopenic thrombocytopathy. Am J Hematol. 1988;27:291-8.CrossRefPubMed
go back to reference McKeown LP, Connaghan G, Wilson O, et al. 1-desamino-8-arginine-vasopressin corrects the hemostatic defects in type 2B von Willebrand's disease. Am J Hematol. 1996;51:158-63.CrossRefPubMed McKeown LP, Connaghan G, Wilson O, et al. 1-desamino-8-arginine-vasopressin corrects the hemostatic defects in type 2B von Willebrand's disease. Am J Hematol. 1996;51:158-63.CrossRefPubMed
go back to reference Casonato A, Steffan A, Pontara E, et al. Post-DDAVP thrombocytopenia in type 2B von Willebrand disease is not associated with platelet consumption: Failure to demonstrate glycocalicin increase or platelet activation. Thromb Haemost. 1999;81:224-8.PubMed Casonato A, Steffan A, Pontara E, et al. Post-DDAVP thrombocytopenia in type 2B von Willebrand disease is not associated with platelet consumption: Failure to demonstrate glycocalicin increase or platelet activation. Thromb Haemost. 1999;81:224-8.PubMed
go back to reference Castaman G, Rodeghiero F, Lattuada A, et al. Desmopressin-induced thrombocytopenia in type I platelet discordant von Willebrand disease. Am J Hematol. 1993;43:5-9.CrossRefPubMed Castaman G, Rodeghiero F, Lattuada A, et al. Desmopressin-induced thrombocytopenia in type I platelet discordant von Willebrand disease. Am J Hematol. 1993;43:5-9.CrossRefPubMed
go back to reference Weinstein RE, Bona RD, Altman AJ, et al. Severe hyponatremia after repeated intravenous administration of desmopressin. Am J Hematol. 1989;32:258-61.CrossRefPubMed Weinstein RE, Bona RD, Altman AJ, et al. Severe hyponatremia after repeated intravenous administration of desmopressin. Am J Hematol. 1989;32:258-61.CrossRefPubMed
go back to reference Shepherd LL, Hutchinson RJ, Worden EK, et al. Hyponatremia and seizures after intravenous administration of desmopressin acetate for surgical hemostasis. J Pediatr. 1989;114: 470-2.CrossRefPubMed Shepherd LL, Hutchinson RJ, Worden EK, et al. Hyponatremia and seizures after intravenous administration of desmopressin acetate for surgical hemostasis. J Pediatr. 1989;114: 470-2.CrossRefPubMed
go back to reference Dunn AL, Powers JR, Ribeiro MJ, et al. Adverse events during use of intranasal desmopressin acetate for haemophilia A and von Willebrand disease: a case report and review of 40 patients. Haemophilia. 2000;6:11-4.CrossRefPubMed Dunn AL, Powers JR, Ribeiro MJ, et al. Adverse events during use of intranasal desmopressin acetate for haemophilia A and von Willebrand disease: a case report and review of 40 patients. Haemophilia. 2000;6:11-4.CrossRefPubMed
go back to reference Fernandez Lucas M, Liano F, Navarro JF, et al. Acute-renal-failure secondary to antifibrinolytic therapy. Nephron. 1995; 69:478-9.CrossRefPubMed Fernandez Lucas M, Liano F, Navarro JF, et al. Acute-renal-failure secondary to antifibrinolytic therapy. Nephron. 1995; 69:478-9.CrossRefPubMed
Metagegevens
Titel
Diagnostiek en behandeling van de ziekte van Von Willebrand
Auteurs
Dr. K. Fijnvandraat
J. C. J. Eikenboom
Publicatiedatum
01-10-2007
Uitgeverij
Bohn Stafleu van Loghum
Gepubliceerd in
Tijdschrift voor Kindergeneeskunde / Uitgave 5/2007
Print ISSN: 0376-7442
Elektronisch ISSN: 1875-6840
DOI
https://doi.org/10.1007/BF03061695

Andere artikelen Uitgave 5/2007

Tijdschrift voor Kindergeneeskunde 5/2007 Naar de uitgave

Boekbesprekingen

Boekbesprekingen